OrbiMed’s Cardiff Oncology CRDF Stock Holding History

OrbiMed’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-573,884	Closed	-$1.8M	–	104
2025 Q1	$1.8M	Sell	573,884 -964,578	-63%	-$3.81M	0.04%	94
2024 Q4	$6.68M	Buy	+1,538,462	New	+$4.81M	0.14%	77

Other funds holding CRDF

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OrbiMed's CRDF Position: Q2 2025 in Review

OrbiMed sold out of Cardiff Oncology (CRDF) in Q2 2025, closing a stake of 573,884 shares — an estimated $1.8M sold.

OrbiMed first reported a position in CRDF in Q4 2024 and held it in 2 quarters. The position peaked at $6.68M in Q4 2024. 114 funds tracked by Wall St. Rank hold CRDF as of Q2 2025.

OrbiMed reported no remaining Cardiff Oncology position as of Q2 2025 after selling out during the quarter.
OrbiMed sold 573,884 Cardiff Oncology shares in Q2 2025, an estimated $1.8M.
OrbiMed first reported a position in Cardiff Oncology in Q4 2024 and held it in 2 quarters.
OrbiMed's Cardiff Oncology position peaked at $6.68M in Q4 2024.
114 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2025.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.